Navigation Links
Vanda Pharmaceuticals Reports Second Quarter 2009 Results
Date:8/10/2009

first quarter of 2009 and $0.51 for the second quarter of 2008.

OPERATIONAL HIGHLIGHTS

On May 6, 2009, the FDA granted U.S. marketing approval of Fanapt(TM) for the acute treatment of schizophrenia in adults. Vanda expects to make Fanapt(TM) available in U.S. pharmacies later this year. Holders of a New Drug Application (NDA) have 60 days after approval to file for patent term restoration under the Hatch-Waxman Act. Vanda submitted its application for patent term restoration with respect to Fanapt(TM) on June 9, 2009.

Vanda also continues to pursue its clinical development plan for tasimelteon for the treatment of circadian rhythm sleep disorders. On June 26, 2009, Vanda met with the FDA to discuss the clinical development plan in an End of Phase II Meeting. Vanda will continue to work with the FDA to characterize the path to an NDA for tasimelteon.

FINANCIAL DETAILS

  • Operating Expenses. Second quarter 2009 R&D expenses of $7.2 million consisted primarily of $5.4 million of consulting fees, as well as $0.6 million of salaries and benefits, $0.6 million of non-cash stock based compensation costs for R&D personnel, and $0.3 million of pre-clinical work. This compares to $2.3 million for the first quarter of 2009 and $5.5 million for the second quarter of 2008. The increase in R&D expenses in the second quarter of 2009 relative to the first quarter of 2009 and second quarter of 2008 is primarily due to the $5.0 million in regulatory consulting fees paid and/or accrued as a result of the approval of Fanapt(TM) by the FDA.

  • General and administrative (G&A) expenses of $5.0 million for the second quarter of 2009 consisted primarily of $0.5 million of salaries and benefits and $2.2 million of non-cash stock based compensation costs for G&A personnel, as well as $0.6 mill
    '/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
3. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
6. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
7. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
8. Vanda Pharmaceuticals Reports First Quarter 2009 Results
9. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
10. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
11. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... -- Senomyx , Inc. (NASDAQ: ... science technologies to discover, develop, and commercialize novel ... supply industries, today reported financial results for the ... quarter with $33.6 million in cash and highly ... quarter Senomyx achieved another important milestone with the ...
(Date:7/31/2014)... 2014 The global market for molecular ... 2020, according to a new study by Grand View ... and the subsequent introduction of advanced cancer diagnostic technologies ... over the next six years. Moreover, the growing global ... cancer, coupled with disease triggering lifestyle habits such as ...
(Date:7/31/2014)... The Kidney Cancer Association (KCA) has established a CNN ... Cancer News. , Bill Bro, KCA CEO, says, “We’re ... an international news organization. When we began using iReport last ... month’s program highlights news of an enzyme that is lost ... study. Kidney Cancer News also presents a report on outcomes ...
(Date:7/30/2014)... W. R. Grace & Co. (NYSE: ... REVELERIS® Prep purification system , a dual-mode instrument ... researchers to perform both flash and preparative liquid ... the REVELERIS® Prep purification system, researchers can easily ... a simple touch of the screen, giving them ...
Breaking Biology Technology:SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 2Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 3Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 5Grace Launches New REVELERIS® Prep Purification System 2
... January 12 Bavarian Nordic,owns several United States ... core technology, MVA-BN(R), which is the basis for ... a vector for delivering,recombinant vaccines. Bavarian Nordic has ... infringement action. The claim in this case is ...
... ALAMEDA, Calif., Jan. 12 Singulex, Inc. today announced ... led by JAFCO Co., Ltd. and supported by existing ... round will support the commercialization of Singulex technologies in ... Hozoji, investment officer for JAFCO Life Science Investment, will ...
... Pharmaceuticals today,announced that it has achieved its first candidate ... GlaxoSmithKline. Anacor may,receive future milestone payments and royalties ... sales. , "We are pleased ... result of,the alliance we have built between our team ...
Cached Biology Technology:Bavarian Nordic's Case Against Oxford BioMedica 2Singulex Closes $19 Million Financing Round 2Anacor Achieves Milestone from GSK for Boron-Based Systemic Antibacterial Product Candidate 2
(Date:7/31/2014)... GAINESVILLE, Fla. --- By tracing nearly 3,000 genes ... moths, University of Florida scientists have created an ... to use large-scale, next-generation DNA sequencing. , ... more closely related to small moths than to ... how butterflies evolved. The study also found that ...
(Date:7/31/2014)... Latinos are the largest minority group in the United ... of Latinos are obese and are 1.2 times as ... , NYU College of Nursing student researcher Lauren Gerchow, ... factors that contribute to this problem by compiling a ... patterns in Latina women recently published in Nursing ...
(Date:7/31/2014)... known that biomass burning burning forests to ... , slash-and-burn agriculture and wildfires figures into ... until the release of a new study by ... Z. Jacobson, the degree of that contribution had ... in a paper published July 30 in the ...
Breaking Biology News(10 mins):UF study advances 'DNA revolution,' tells butterflies' evolutionary history 2UF study advances 'DNA revolution,' tells butterflies' evolutionary history 3NYU research looks to combat US Latina immigrant obesity 2Stanford professor finds that wildfires and other burns play bigger role in climate change 2Stanford professor finds that wildfires and other burns play bigger role in climate change 3Stanford professor finds that wildfires and other burns play bigger role in climate change 4
... are important vehicles for the transmission of enteric ... including human pathogens, are particularly abundant in bivalve ... procedures, thus representing a potential risk for human ... to affect the persistence of vibrios in these ...
... population of North Pacific right whales, found during the summer ... whale populations in the world. Commercial whaling in the 1800s ... these whales have been recognized as a different species from ... the Southern Hemisphere. , To help define areas and ecological ...
... in northern China starting as far back as 2400 ... farming combined with other crops, says University of Toronto ... with Chinese agriculture, most archeologists have, until recently, thought ... food associated with northern China. However, recent archeological research ...
Cached Biology News:Edible bivalves as a source of human pathogens: signals between vibrios and the bivalve host. 2Habitat use by North Pacific right whales, Eubalaena japonica, in the Bering Sea and Gulf of Alaska 2
Ubiquitin Related I Sampler Kit 10 mu g each...
Chaperone Sampler Kit 10 mu g each...
Zonula Adherens Sampler Kit 10 mu g each...
Tumor Suppressor Sampler Kit 10 mu g each...
Biology Products: